Dianthus Therapeutics, Inc. DNTH
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 64.36% | 63.03% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 64.36% | 63.03% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 64.36% | 63.03% | |||
| SG&A Expenses | 8.73% | 25.86% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 32.44% | -32.69% | |||
| Operating Income | -32.13% | 33.09% | |||
| Income Before Tax | -22.97% | 36.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -22.97% | 36.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -22.97% | 36.62% | |||
| EBIT | -32.13% | 33.09% | |||
| EBITDA | -32.14% | 33.11% | |||
| EPS Basic | -5.42% | 40.66% | |||
| Normalized Basic EPS | -14.95% | 40.37% | |||
| EPS Diluted | -5.42% | 40.66% | |||
| Normalized Diluted EPS | -14.95% | 40.37% | |||
| Average Basic Shares Outstanding | 16.65% | 6.81% | |||
| Average Diluted Shares Outstanding | 16.65% | 6.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||